With a key approval decision less than two months away, Amarin (AMRN) said Wednesday that the Food and Drug Administration is “unlikely” to convene an advisory committee meeting to review data on an expanded use of its heart drug Vascepa.

Amarin’s statement, offered as an update with its second-quarter earnings announcement, was meant to quell any residual investor concerns about the FDA’s ongoing review of Vascepa — with a decision deadline of Sept. 28. 

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Adam, can you supply the citation for the study showing ” 25% reduction in the risk of bad cardiovascular events like heart attacks and strokes” with Vascepa treatment? Thanks!

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy